Adsorption of human blood plasma on nanodiamond and its influence on activated partial thromboplastin time  by Mona, J. et al.
Diamond & Related Materials 39 (2013) 73–77
Contents lists available at ScienceDirect
Diamond & Related Materials
j ourna l homepage: www.e lsev ie r .com/ locate /d iamondAdsorption of human blood plasma on nanodiamond and its inﬂuence on
activated partial thromboplastin time☆J. Mona a, C.-J. Kuo a, E. Perevedentseva a,b, A.V. Priezzhev c, C.-L. Cheng a,⁎
a Department of Physics, National Dong Hwa University, 97401 Hualien, Taiwan
b P. N. Lebedev Physics Institute, Rus. Acad. Sci., 119991 Moscow, Russia
c Department of Physics, International Laser Center, M.V. Lomonosov Moscow State University, Vorob'evygory, 119991 Moscow, Russia☆ Presented at the New Diamond and Nanodiamond
May 19–23, 2013.
⁎ Corresponding author at: Department of Physics, Na
Sec. 2 Da Hsueh Rd., Shoufeng, 97401 Hualien, Taiwan
E-mail address: clcheng@mail.ndhu.edu.tw (C.-L. Che
0925-9635 © 2013 The Authors. Published by Elsevier B.V
http://dx.doi.org/10.1016/j.diamond.2013.08.001a b s t r a c ta r t i c l e i n f oAvailable online 23 August 2013Keywords:
Nanodiamond
Human blood plasma
Adsorption
Blood coagulationEver increasing use of engineered nanodiamond (ND) into the human blood for various biomedical studies and
applications has increased the demand to thoroughly understand the interaction of NDs with blood and its effect
on blood coagulation. Here, we report on the study of adsorption of human blood plasma on various sized
carboxylated nanodiamonds (cNDs) using UV/visible spectroscopy and Fourier transform infrared spectroscopy
(FTIR). The adsorption of human blood plasma on 5 nm and 100 nm sized cNDs is conﬁrmed from UV/visible
spectra. FTIR shows minor change in the shape of amide I absorption peak (1600–1700 cm−1) indicating that
the protein secondary structure remains unaffected for human blood plasma. The inﬂuence of cNDs on the
blood coagulation has been estimated using Activated Partial Thromboplastin Time (APTT) test. The APTT test
is one of the standard tests used to investigate the efﬁcacy of the intrinsic pathways of coagulation. The APTT
test results indicate that 5 and 100 nm cNDs with various concentrations (10–500 μg/ml) do not show delay
in time when coagulation was initiated through the intrinsic pathway.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
In recent years, research on the biomedical applications of nano-
diamond (ND) has increased substantially, especially in the ﬁelds of
drug delivery (i.e. cancer therapeutics) [1–4], photoluminescent/Raman
biomarker and bioprobes [5–7], nanosurgery [1], prosthetic devices for
retinal implants [1], analytical diagnostics [1], biosensors [8], and
bio-chips [9], etc. These applications directly beneﬁt from various
interesting properties of NDs, such as optical and spectroscopic
properties [7,10,11], high chemical stability, special structure/surface
[1] as well as extremely low toxicity to various animal cells and living
organisms [7,11–13]. In addition to these properties, ND's surface with
relatively large number of surface atoms makes them amenable for
functionalization/conjugation with various bio/medical molecules/
drugs of interest [14,15]. ND's effect on the function of biological
objects, such as whole organisms, individual organs, tissues and
ND's interactions with blood and its components are important to
understand.(NDNC) Conference, Singapore,
tional Dong Hwa University, 1,
.
ng).
. Open access under CC BY-NC-ND licIn particular, for the research related to nanoparticle's application in
biomedicine, it is mandatory to inject nanoparticles in blood. Recently,
many investigations of nanoparticle interactions with blood and blood
components have been performed. The extent of protein adsorption
such as albumin, immunoglobulins, ﬁbrinogen, histone, insulin, etc.
from blood plasma, on different types of nanoparticles of various size
and surface chemistry has been investigated [16–19]. Wasdo et al.
identiﬁed 69 unique proteins that exhibited adsorption to various
nanoparticles [20]. Uptake of blood electrolytes from simulated
blood ﬂuid (SBF) and the stability (by dispersion/aggregation) of
nanoparticles in SBF have been examined [21]. Effects of various
nanoparticles on red blood cell hemolysis and blood clotting parameters
have beenmeasured [9,21–23]. Humanplatelet aggregation in-vitro and
rat vascular thrombosis in-vivo using engineered carbon nanoparticles
have been studied [24]. Blood platelet activation with inducing extra-
cellular Ca2+ inﬂux and with a marked release of platelet membrane
microparticles positive for the granular secretion markers along with
platelet aggregating activity has been analyzed using carbon nanotubes
[25].
As for ND, interaction of ultraﬁne detonated ND with whole blood
affects blood's some biochemical characteristics by causing destruction
ofmammalian cells, but serious blood cell destructionwas not observed
[9]. Wasdo et al. studied the interactions of blood plasma proteins
(albumin and γ-globulin) with nanoparticles including NDs [20]. They
found low afﬁnity of both albumin and γ-globulin to nanoparticles in
in-vitro conditions. The inﬂuence of ND interaction on the oxygenation
and de-oxygenation states of hemoglobin and micro rheologicalense.
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used effectively as bio-label and drug delivery tool in ambient conditions,
without complicating the blood's physiological conditions [23].
Mostly, hemolytic properties are used as oneof the common tests for
understanding nanoparticle interactions. Hemolytic effect was quanti-
tatively estimated for 5 and 100 nm carboxylated NDs (cNDs) and the
hemolysis did not exceed 2 to 4% as compared with hemolysis created
by Triton X-100 [23]. Another important test is blood coagulation.
When the blood is exposed to exogenous factors (like tissue damage)
blood coagulation is activated and this leads to generation of thrombin
and ﬁbrin clot that stops the bleeding. Thus, it is important to determine
whether cNDs could affect the coagulation factors.
Carbon nanoparticle induced platelet aggregation and vascular
thrombosis was studied by Radomski et al. [24]. It is important to
mention that carbon single-wall and multi-wall nanotubes and
amorphous carbon nanoparticles are clearly different when it
comes to their platelet reactivity. Effects of CNT on prothrombotic
mechanisms and vascular toxic effects have been discussed [25]. As
for detonation diamond nanoparticles, cNDs evoked signiﬁcant
activation of human platelets and in vivo pulmonary thromboembolism
[26]. However, rarely any research exists on ND effects on blood
clotting. Studies concerning the blood components' interaction with
diamond-like carbon (convenient sp3/sp2 ratio, hydrogenation state)
and nano-crystalline diamond (good structure without defects) thin
ﬁlm surfaces demonstrated high level of resistance to blood platelet
adhesion and thrombus formation [27–29]. This has been explained
by signiﬁcantly reduced plasma protein adhesion to such surface. In
contrast to this observation, signiﬁcantly large amount of blood plasma
proteins on the diamond nanoparticles has been reported [16,30].
Morphology and coagulation of human blood cells attached to
borosilicate glass and diamond substrates were compared [31]. It
was shown that diamond surface is less thrombogenic than the
glass surface, thus indicating that diamond could be an attractive
material for future designing of prostheses and medical devices
such as surgery instruments, blood pumps and artiﬁcial hearts.
As a consequence, it is absolutely essential for researchers to pay
close attention to interactions of NDs with blood and its components
and study its blood coagulation compatibilities. In the present work,
we have studied the interaction of cND (5 and 100 nm) with human
bloodplasma. UV–visible absorption has beenused to observe the loading
of blood plasma on cND. FTIR spectroscopy and ζ-potential measure-
ments were used to access the structural changes. In addition, the
inﬂuence of ND on the blood coagulation is quantiﬁed using Activated
Partial Thromboplastin Time (APTT) test, which is one of the standard
tests used to investigate the efﬁcacy of the intrinsic pathways of
coagulation.
2. Experimental procedure
Synthetic diamond powders with nominal particle sizes of 5 and
100 nm were purchased from Microdiamont AG, Switzerland and Kay
Diamond, USA respectively. Previously it was reported that after
carboxylation of diamond the surface molecular and ionic groups
facilitate the interaction of diamond with biomolecules and show
better biocompatibility [32,33]. Therefore, the diamond powders
were carboxylated (referred to as cND) using strong acid treatments
to create carboxyl groups and to clean the surface admixtures, defects,
and impurities according to the methods described earlier [32,33].
The experiments usinghuman subjectswere coherent to the national
regulation of Human Subject Research (Taiwan) and the Declaration of
Helsinki. To achieve the purpose, we had formally obtained written
and signed consent from all the volunteers, the PI, aswell as the students
who performed the experiments and had taken lectures concerning
ethical issues. Theprotocol is approvedby the research ethics committee,
Tzu Chi General Hospital, Hualien Taiwan. The committee is organized
under, and operates in accordance with, the good clinical practiceguidelines and governmental laws and regulations. 5 ml of whole
blood was withdrawn from healthy volunteers with the use of EDTA as
anticoagulant. The plasma fraction was separated by centrifugation at
1500 rpf for 5 min at 4 °C and the whole supernatant was deﬁned as
plasma which was platelet-poor plasma. For interaction of cND with
plasma, 2 mg of cNDs were dispersed in 1 ml of plasma and were
allowed interacting uniformly using vortex at 37 °C for 2 h. After 2 h
through agitation, the mixture was centrifuged at 11000 rcf for 10 min
to separate the unreacted plasma components present in supernatant.
The supernatant was subject to three times washing to remove the
non-interacted plasma. The supernatant was decanted and this suspen-
sion was used to measure the UV/vis absorption spectra which were
recorded using a Jasco V550 UV/visible spectrophotometer (JASCO
International Co., LTD., Tokyo, Japan). The sediment (cND interacted
with plasma) was dispersed in 1 ml of standard phosphate buffer
saline (PBS: NaCl 0.4 g; KCl 0.01 g, Na2HPO4 0.072 g, KH2PO4
0.021 g; H20 50 ml; pH 7.5) by ultrasonication for 15 min followed
by vortex for 10 min. The process of washing was done thrice to
completely remove the un-reacted plasma. The cND–plasma complex
was centrifuged at the rate of 3400 rpf for 1 min and the cND–plasma
complex sediment was dropped on Si substrate and dried naturally.
FTIR spectrum of dried cND–plasma complex on Si substrate was
obtained using BomemMB154 spectrometer equippedwithMCT liquid
nitrogen cooled detector. The spectrumwas recorded in the scan range
of 400–4000 cm−1. The ζ-potential of plasma, 5 nm and 100 nm cNDs
and cND–plasma was determined for pH 7.5 using the Zetasizer
Nano-ZS, Malvern instruments, UK. The effect of NDs on plasma coagu-
lation activity was performed using Activated Partial Thromboplastin
Time (APTT) test. For APTT determination, various concentrations
(10 μg/ml, 100 μg/ml, 500 μg/ml) of cND–plasma complexes were
incubated at 37 °C for 60 s. Actin FSL activating reagent (Siemens,
Germany) was added and the mixture was incubated for 180 s. The
reaction was monitored for 190 s, after the addition of 50 μl of calcium
chloride. Plasma coagulation experiments were performed using a
Sysmex CA-50 plasma coagulation analyzer from Sysmex Corporation
(Kobe, Japan).
3. Results and discussion
Fig. 1 shows the absorption spectra of plasma before and after inter-
action (supernatant of plasma) with 5 nm and 100 nm cNDs at
pH ~ 7.5. The difference in the absorption before and after interaction
exempliﬁes the amount of plasma components adsorbed on cND
particles. It can be seen that 5 nm cND adsorbs more amount of
components of blood plasma as compared to 100 nm cND. This is
probably because, for 5 nm cND, the total surface area is larger and
the surface structure is different than 100 nm cND. Additionally,
the electrostatic interaction plays an important role for studying
the interaction of plasma with the surface of cND. The charge state
of cND has been characterized using ζ-potential measurements for
plasma, 5 and 100 nm cNDs, and cND–plasma as shown in Fig. 2.
Measurements were performed at pH ∼ 7.5. The ζ-potentials are
negative, for plasma it is ~−5 mV (average for the plasma compo-
nents), for 5 nm and 100 nm before interaction they are ~−8 mV
and ~−22 mV, respectively. After plasma absorption ζ-potentials
shift to ~−5 mV for 5 nm cND and ~−20 mV for 100 nm cND. The
ζ-potential becomes less negative because the adsorption of less
electronegative components from plasma decreases the electronega-
tivity of the complex on the surfaces, which results in the variation of
the ζ-potential.
FTIR spectroscopy is sensitive to ND's surface molecular and ionic
groups and usually used for analysis of ND's surface. Measured FTIR
spectra for human blood plasma, 5 and 100 nm cNDs and cND–
plasma complexes are displayed in Fig. 3. Fig. 3((a, b)-i) shows the
spectra of pristine 5 and 100 nm cND particles. The most prominent
absorption bands after carboxylation are related to C_O stretching
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Fig. 1. Absorbance spectra for interaction of plasma with 5 nm and 100 nm cNDs.
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compound and its environment. Hydroxyl-containing groups (~1630–
1640 cm−1, 3400 cm−1), the absorption bands at 2923 cm−1 and
2855 cm−1 are asymmetric and symmetric vibrations of C\Н
group, and the absorption bands between 1100–1140 cm−1 and
1360–1420 cm−1 are C\O\C and C\OH bonds [33,34].-25
-20
-15
-10
-5
0
5
10
Plasma 5 cND
Plasma
before adsorption
after adsorption
ζ-p
ot
en
tia
l (m
V)
pH 7.5
100 cND
Fig. 2. The dependence of the ζ-potential of plasma and 5 nm and 100 nm cNDs before
and after adsorption at pH 7.5.Bloodplasma containsmany components such as proteins, hormones,
ferments, clotting factors, electrolytes, glucose, waste products, minerals,
etc., and they can absorb in different regions of the IR spectrum. Proteins
are the main component of the plasma. Proteins adsorption, adsorbed
protein structure and functional state can be analyzed with infrared
spectroscopy by analyzing the amide peaks which are sensitive to
protein conformation and closely connected with the protein func-
tionality. And amide I is the most widely used vibrational mode to
determine conformations of proteins [35].
Absorption bands in Fig. 3((a, b)-ii, iii) centered near 1653 cm−1
(1600–1700 cm−1) observed in the spectra recorded for blood plasma
before and after interaction of cNDs are assigned as amide I, arising
mainly from the C_O stretching vibration with minor contributions
from the out-of-phase CN stretching vibration, the CCN deformation,
and the NH in-plane bend [36]. The amide II peak at around 1541 cm−1
is the out-of-phase combination of the NH in-plane bend and the CN
stretching vibration with smaller contributions from the CO in-plane
bend and the CC and NC stretching vibrations. Amide III has absorption
bands in the range 1200–1400 cm−1 which arises due to the in-phase
combination of the NH bending and CN stretching vibration with small
contributions from the CO in-plane bending and CC stretching vibration.
Other absorption bands are amides A and B (3000–3300 cm−1). Usually,
these amide peaks are characteristic to almost all the proteins. From the
ﬁgure it can be seen that after plasma adsorption the amide I and amide
II peaks are more intense and dominate the OH and C_O absorption
peaks of cND. Also, the shape of amide I and amide II absorption peak
changes. The amide I peak is the most well-attributed and sensitive to
protein, so this peak is used to observe changes in the secondary structure
for protein conformation [37–39]. As reported earlier, amide I was
represented as superposition of peaks assigned to different secondary
structures i.e. 1663–1695 cm−1 for β-sheet or β-turn structures,
1650–1662 cm−1 for α-helices, 1644–1648 cm−1 for random chains
and 1618–1642 cm−1 for β-sheets [30]. Bands at lower wavenumbers
(1616 cm−1) have been assigned to side chain moieties. As we observe
the slight change in the shape of amide I peak, which is connected to
relative decreasing of β-sheet fraction (relative decreasing intensity
in ranges 1600–1640 cm−1 and 1665–1690 cm−1). α-helix structure
still dominates, that indicate that adsorbed proteins stay in their native
state.
A critical component of the blood coagulation cascade is ﬁbrinogen.
It is themost abundant protein in the elution from the colloidal surfaces.
Blood coagulation involves a series of proteolytic reactions resulting in
the formation of ﬁbrin clot. Thrombin is formed following a cascade
reactions where an inactive factor becomes enzymatically active after
proteolytic cleavage by other enzymes and the newly activated enzyme
then activates another inactive precursor factor. The Activated Partial
Thromboplastin Time (APTT) is generally used to assess coagulation
disorders in patients with abnormal bleeding due to deﬁciencies within
the intrinsic coagulation cascade which tend to induce prolonged APTT
reactions. The APTT also governs how a biomaterial affects the coagula-
tion time. The enzymatic activities that lead to clot formation are
estimated through APTT measurement. Varying parameters of blood
can also be studied for analyzing the blood clotting factors [21,24,25].
Here we have examined the interaction of the plasma ﬁbrinogen with
the 5 and 100 nm cND particles and their inﬂuence on blood coagulation
is studied using APTT. The APTT is mostly used to evaluate the intrinsic
coagulation pathway. For a ﬁbrin clot to form in plasma requires few
seconds after the addition of partial thromboplastin reagent (i.e. actin)
and calcium chloride to the samples. The APTT results of plasma
(control), 5 nm and 100 nm cNDs and cND–plasma complex are
shown in Fig. 4. The control APTT time for a healthy blood plasma
was regarded to be about 30.8 s.When the blood plasma is incubated
with 5 nm and 100 nm cNDs with various concentrations, the
corresponding data of APTT were 30.1 s and 30.9 s for 10 μg/ml,
29.8 s and 30.1 s for 100 μg/ml, and 30.5 s and 31.0 s for 500 μg/ml,
respectively. There was no signiﬁcant difference observed in the
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Fig. 3. FTIR spectra of interaction of (a) 5 nm and (b) 100 nm cNDs with human blood plasma. The marked i, ii and iii are cND, cND + plasma and plasma, respectively.
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trations in blood plasma. Also, 5 and 100 nm cNDs with higher
concentration (500 μg/ml) did not affect the APTT clotting factor
and the values were compatible. The results indicate that cNDs in
human blood plasma are blood compatible.0
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Fig. 4. APTT clotting test for interaction of plasma with 5 nm and 100 nm cNDs.4. Conclusions
Understanding of blood components' interaction with NDs is
signiﬁcantly important for ND biomedical applications. For in-vivo
experiment, ND–drug complex can be affected by the blood plasma
or cells, so the delivery and the effect of drug can be disrupted. On
the other hand, NDs can affect the blood cell (and other components)
properties and functions, inﬂuence on processes in blood e.g. to vary
cell aggregation, change RBC rheological and oxygen-transport
properties, and affect osmotic properties of the plasma. The plasma
components can reveal differential binding (adsorption) on ND,
which can change the plasma components and relative concentrations.
In this work we see adsorption of plasma on 5 nm and 100 nm cNDs,
and importantly, we do not observe any signiﬁcant change of blood
plasma protein conformation. The properties and functioning of
the blood plasma components are essential for the development
of in-vivo bio-applications of nanoparticles including NDs. The effect
of 5 nm and 100 nm cNDs with various concentrations on blood
clotting was estimated. Even at high concentrations of the cNDs (up to
500 μg/ml), no effect on coagulation was observed when the intrinsic
pathway was followed by APTT test. The results showed that there
was no signiﬁcant difference and the values were compatible before
and after interaction of cNDwith plasma. Through this reportwe present
selected conditions of safety and effectiveness ofNDs for bio-applications.
Prime novelty statement
Through this paper, we present the interaction of nanodiamond
(ND) with human blood plasma. We have shown that after interaction
of carboxylated ND with blood plasma, there is no signiﬁcant change
of blood plasma protein conformation. The APTT test results show that
5 and 100 nm cNDs with various concentrations (10–500 μg/ml) do
not show delay in time when coagulation was initiated through the
intrinsic pathway and indicate that the cNDs in human blood plasma
are blood compatible. This research is important because for
nanoparticle's application in biomedicine it is mandatory to inject
nanoparticles in blood so it is necessary to investigate the interaction
of ND with blood and blood components.
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